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SUMMARY
An experimental oil-adjuvanted, inactivated vaccine against bovine herpesvirus type 1 (BHV-1.1), was produced and evaluated in
its capacity to induce neutralizing antibodies against bovine herpesvirus type 1 (BHV-1, subtypes 1.1 and 1.2) and bovine herpesvirus
type 5 (BHV-5). Cattle were vaccinated and revaccinated 90 days later. Antibodies were measured at days 0, 30, 90, 120, 180, 270
and 450 days after the first dose of vaccine (DPV). Antibody titres to BHV-1.1 and BHV-1.2 were significantly higher than to
BHV-5 throughout the experiment. While all calves seroconverted to BHV-1.1 and BHV-1.2 after the first dose of vaccine, only
two out of 23 (8,7%) calves seroconverted to BHV-5. However, after the booster injection all animals seroconverted to the three
virus types. At 450 DPV, 79% (15/19 cattle) and 84% (16/19) were still positive for antibodies to BHV 1.1 and BHV 1.2, whereas
50% (10/19) of the calves remained seropositive for BHV-5. It was concluded that although a potent BHV-1 vaccine may induce
crossreactive neutralizing antibodies to BHV-5, the levels of such antibodies are significantly lower and of shorter duration than
antibodies to BHV-1.1 or BHV-1.2.
UNITERMS: BHV-1; BHV-5; Bovine herpesvirus; Experimental vaccine; Inactivated vaccine; Neutralizing antibodies.
INTRODUCTION
ovine herpesvirus type 1 (BHV-1), also known as
infectious bovine rhinotracheitis/infectious pustular
vulvovaginitis (IBR/IPV) virus, and bovine herpesvirus
type 5 (BHV-5) or bovine encephalitis herpesvirus are members
of the family Herpesviridae, sub-family Alphaherpesvirinae15.
BHV-1 has been divided into subtypes BHV-1.1 and BHV-1.2,
based on monoclonal antibody and restriction enzyme analysis5,14.
BHV-1 is a major pathogen of cattle, widespread in its geographical
distribution, affecting cattle of all ages and breeds. Although rarely
fatal after post-natal infections, BHV-1 can be responsible for
significant economic losses due to reproductive and respiratory
disease. On the other hand, data on BHV-5 geographical
distribution is scarce. The virus has been more often detected in
the southern hemisphere, affecting usually young cattle with low
morbidity whereas mortality rates approach 100%5,8,10,18,20. Despite
the large number of different BHV-1 vaccines in the market, no
commercially available vaccine has been specifically designed to
BHV-5. As a consequence to that, a common practice is to
vaccinate against BHV-1 when BHV-5 infections are diagnosed,
in attempting to reduce mortality. However, the efficacy of such
procedure has not yet been determined. Therefore, it is of interest
to evaluate whether BHV-1 vaccines would protect against BHV-
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5 infections. As part of such evaluation, the present study was
carried out to examine the neutralizing antibody responses induced
to BHV-1.1, .2 and BHV-5 by a highly potent antibody inducer,
oil-adjuvanted, inactivated BHV-1 vaccine.
MATERIAL AND METHOD
Calves
Thirty calves of mixed European breeds, aged between 8
and 15 months, were used in the vaccination experiments. At the
beginning of the experiment, calves had no detectable neutralizing
antibodies to BHV-1 (1.1 and 1.2) and BHV-5, as determined by
serum neutralization tests. Seven of the calves were kept as
unvaccinated controls throughout the experiment.
Virus strains
The BHV-1 strain “Cooper” (subtype 1 or BHV-1.1) was
obtained from the Panamerican Centre for Foot and Mouth
Disease, Rio de Janeiro, Brazil. The BHV-1 isolate EVI 014
(subtype 2 or BHV-1.2) was isolated in 1993 in our laboratory,
from organs of an aborted foetus. The BHV-5 strain EVI 88 was
also isolated in our laboratory in 1995 from a calf which died
with signs of nonpurulent meningoencephalitis in the state of
Mato Grosso do Sul (close to the Pantanal region). Viruses were
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characterized as BHV-1 or BHV-5 using a panel of monoclonal
antibodies described previously19 and by restriction enzyme
analysis5,14.
Cells
Madin Darby bovine kidney cells (MDBK; ATCC CCL-
22) between the 15th and 25th passage number were used for the
multiplication of viruses and preparation of the vaccine. Cells were
multiplied and maintained in Eagle’s minimal essential medium,
supplemented with 8% fetal calf serum (Nutricell), following
standard procedures11. Cells for vaccine production were prepared
in 2-litre roller bottles seeded with 300 ml of suspensions
containing 2 x 105 cells/ ml.
Vaccine production
About 16-24 hours after seeding of the cells, the medium
was removed and bottles infected with 4 x 105,5 tissue culture 50%
infective doses (TCID) of the BHV-1 strain Cooper. After one
hour for adsorption at 37ºC, the inoculum was removed, the bottles
replenished with E-MEM without fetal calf serum and incubated
for 16- 24 hours at 37ºC, when cytopathic effect was evident in
about 90% of the monolayers. Bottles were then shaken to remo-
ve attached cells and stored at 4ºC for 24 hours. The sediment was
then discarded and the infectious titre of the bulk suspension
(supernatant) was determined (107,25 TCID ml-1) following standard
procedures13. The viral suspension was inactivated with binary
ethylenimine (BEI) as described previously2. The vaccine was
prepared as a water-in-oil type emulsion and subjected to usual
controls as recommended17.
Vaccination of cattle
Twenty-three calves were vaccinated intramuscularly in
the cranial third of the neck with 5 ml of the vaccine. Seven other
calves were kept as unvaccinated controls. At day 90 after the
first vaccination, all calves received a booster injection. Blood
samples were collected at days 0, 30, 90, 120, 180, 270 and 450
after the first dose of vaccine.
Neutralizing antibody titres
Neutralizing antibody levels were measured against the
homologous vaccine virus (Cooper strain), against the isolate EVI
014 and against the BHV-5 strain EVI 88. Antibodies were titrated
by the constant virus-varying serum dilution as described7, with
100 TCID of each virus against twofold serum dilutions (from 1/
2 onwards).
Statistical analysis
The results of the neutralizing antibody titres were
submitted to the transformation: log (y+10). Statistical analysis
was performed using the analysis of variance in a model of
subdivided parcels, considering the calves as blocks, the main
parcel being the three different viruses; the interaction between
virus type and animal, the error. In each subparcel, time (in days)
and the interaction “days plus virus” were considered. For the
comparison between the averages of the neutralizing antibody titres
for the different viruses the Student-Newman-Keuls analysis was
employed. For the comparison of titres in different days the method
of orthogonal polinomia was used. The level of significance
adopted was 0.05.
RESULTS
The mean neutralizing antibody titres induced by the ex-
perimental vaccine against BHV-1 and BHV-5 are shown in Tab. 1.
At the beginning of the experiment, all animals, including the control
unvaccinated cattle, were negative for neutralizing antibodies to the
three herpesviruses (BHV-1.1, BHV-1.2 and BHV-5).
At day 30 after the first dose of vaccine (30 DPV), most
animals seroconverted to BHV-1.1 and BHV-1.2. However, only
one animal became seropositive to BHV-5. At 90 DPV, all
vaccinated calves responded with the production of neutralizing
antibodies to BHV-1.1 and BHV-1.2, whereas 2/23 showed
detectable antibodies to BHV-5. Neutralizing antibody levels were
significantly higher to BHV-1.2 than to the other two viruses. At
day 30 after the booster injection (120 DPV), all 23 calves had
antibodies to the three viruses. However, neutralizing antibody
titres were significantly lower to BHV-5 than to BHV-1.1 or BHV-
1.2. Titres remained significantly lower to BVH-5 than to both
BHV-1 viruses throughout the experiment, up to 450 DPV. On
the other hand, after the booster dose of vaccine, no significant
differences were detected between the neutralizing antibody titres
to BHV-1.1 and BHV-1.2, albeit titres were always about twofold
lower to BHV 1.1 than to BHV-1.2.
The number of animals that seroconverted for the three
virus types up to day 450 after vaccination is shown in Tab. 2.
At 180 DPV, 23/23 calves remained seropositive for both BHV-
1.1 and BHV-1.2. At 450 DPV, 79% (15/19) and 84% (16/19)
of the cattle were seropositive for BHV 1.1 and BHV 1.2,
respectively, while 52% (10/19) of the animals were still seropositive
for BHV-5.
None of the seven unvaccinated control calves developed
neutralizing antibodies to the three viruses tested throughout the
duration of the experiment.
Table 1
Mean neutralizing antibody titres and number of cattle seropositive to
BHV-1.1, BHV-1.2 and BHV-5, after vaccination with an inactivated,
oil-adjuvanted anti-BHV-1 vaccine.
Serum neutralization tests performed against BHV-1.2 (EVI 014) and
BHV-5 (EVI 88) as described in methods. (**) Booster carried out at
90 days post-vaccination. Bold numbers refer to statistically significant
differences (p < 0.05). µ: mean neutralizing antibody titre; σ: standard
deviation. Titres expressed as the reciprocal of the neutralizing
antibody titre.
0 30
Days post vaccination
90** 120 180 270 450
Antibodies to:
< 2 7.26 3.87 107.83 36.13 23.67 10.90
BHV-1.1
4.71 6.68 100.19 45.39 22.95 11.17
< 2 10.25 9.60 201.83 28.18 22.32
BHV-1.2
5.5 9.86 159.79 90.59 29.41 11.04
< 2 0.17 0.40 30.3 4.84 3.58
BHV-5
m
s
m
s
m
s 0.83 1.43 29.07 10.12 4.82 4.73
72.43
9.88
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DISCUSSION
In countries of the southern hemisphere, the number of
outbreaks of encephalitic disease from which BHV-5 has been
isolated have increased substantially over the last few years12,18,20.
Studies with paraffin embedded sections have shown that BHV-5
may have been cause of mortality in the past8,9, but only at present
its importance as a major pathogen is being recognised in the field.
Due to the unavailability of a specific BHV-5 vaccine, vaccination
with BHV-1 vaccines in farms where BHV-5 associated disease
occurred has become a common practice in attempting to reduce
losses. However, to date, there is very little experimental data to
support such practice6. Moreover, as BHV-5 encephalitis is a
disease of low morbidity, it is difficult to evaluate the efficacy of
such a procedure under field conditions. In view of that, we aimed
to examine the neutralizing antibody profile of cattle vaccinated
with a highly potent BHV-1 vaccine.
Antibody levels to BHV-1.2 were consistently (about
twofold), despite not always significantly (Tab. 1) higher than those
to the BHV-1.1 homologous vaccinal virus strain. It was not
possible to determine the cause of such unexpected finding. It might
be hypothesized that BHV-1.2 strain was more efficiently
neutralized than the homologous vaccinal virus, perhaps due to
some form of antigen presentation where antibodies had a stronger
affinity for the former than for the latter. However, explanations
for such findings remain merely speculative.
It is well known that the induction of neutralizing
antibodies does not warrant protection. Protection against infection
associated to vaccination would only be consistently evaluated in
a vaccination and challenge trial. The feasibility of such trial in
this particular case suffers from the lack of a virus strain that would
consistently reproduce clinically evident encephalitis under expe-
rimental conditions. Such difficulty has also been encountered by
others4,3,6. Nevertheless, quantitation of neutralizing antibodies
remains as an indirect means of comparison, and as such it was
used here to provide a measure of the extent of crossreactivity of
the immune responses to bovine herpesviruses 1.1, 1.2, and 5.
Although neutralizing antibodies are only a part of several
mechanisms activated in the host’s immune response to
herpesviruses16, antibody analysis has also been adopted in previous
studies for comparisons of BHV-1 and BHV-5 immunogenicity4.
From the results obtained in the present work, it was clear that
crossreactive neutralizing antibodies to BHV-5 were in fact
developed after two injections with the highly antibody inducer,
BHV-1 vaccine. When detected, crossreactive anti-BHV-5
antibodies were always at levels below those attained for BHV-1.1
and BHV-1.2. Therefore, although some crossreactive immune
response was obtained, the results suggest that calves may not be
as prepared to face a BHV-5 challenge as they would to BHV-1.1
or BHV-1.2. Other authors have suggested that the rare occurrence
of BHV-5 in countries where BHV-1 vaccination is practiced might
be a consequence of such immunization6. This would be in
agreement with field observations that, in South American countries,
BHV-5 has been usually detected in farms where vaccination to
BHV-1 was not performed. The observations in the present work
add in favour to this hypothesis. As no BHV-5 vaccine is available
so far, when BHV-5 episodes of disease are detected, it might be
advisable to proceed to BHV-1 vaccination in attempting to
minimise BHV-5 associated losses. Nevertheless, as clinically
evident BHV-5 infections are not the rule, the cessation of cases of
encephalitis after BHV-1 vaccination may not be related to
crossprotection induced by the vaccine. The apparent benefit from
vaccination might be coincidental with the sporadic nature of the
disease. Therefore, it is difficult to assess the efficacy of BHV-1
vaccination on BHV-5 infections under field conditions. Other
authors concluded that vaccination or immunity to BHV-1 was
protective against the development of mild BHV-5-induced lesions
in the brains of calves6. However, they did not succeed in
reproducing clinically noticeable encephalitic disease in BHV-5
infected control calves. Moreover, we have detected considerable
genomic and antigenic variability while examining more than 30
distinct BHV-5 isolates so far1. Such differences may add to the
variables involved in protection induced by vaccination. Thus, the
actual efficacy of protection to BHV-5 after immunization with
BHV-1 remains a matter to be examined in the future, preferably
upon vaccination and challenge experiments. Such experiments
must involve challenge with BHV-5 strains capable of inducing
clinically evident disease to allow appropriate interpretation of the
consequences of immunization.
CONCLUSIONS
It was concluded that although a potent BHV-1 vaccine
may induce crossreactive neutralizing antibodies to BHV-5, the
levels of such antibodies are significantly lower and of shorter
duration than antibodies to BHV-1.1 or BHV-1.2. However, it
remains to be answered whether BHV-1 vaccination would induce
protection to BHV-5 infection or disease. Studies are in progress
to examine this question.
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Table 2
Number of cattle seropositive to BHV-1.1, BHV-1.2 and BHV-5, after
vaccination and boostering with an inactivated, oil-adjuvanted, anti-BHV-
1 vaccine.
Booster vaccination carried out at day 90 post-vaccination. Percentages
refer to number of seropositive over total number of vaccinated cattle. **
Some samples were not available in that particular sampling, thus the
variation in number of examined sera.
0 30 90 120 180 270 450
Seropositive to:
0/23
0
21/21**
100
23/23
100
23/23
100
23/23
100
21/21
100
15/19**
78.9
BHV-1.2
%
0/23
0
21/21
100
23/23
100
23/23
100
23/23
100
20/21
95.2
16/19
84.2
BHV- 5
%
0/23
0
1/23
4.3
2/23
8.7
23/23
100
17/23
73.9
17/21
80.9
10/19
52.6
Days post vaccination
BHV-1.1
%
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RESUMO
Foi avaliada a capacidade de uma vacina experimental oleosa inativada contra o herpesvírus bovino tipo 1 induzir anticorpos contra o
herpesvírus bovino tipo 1 (BHV-1.1 e BHV-1.2) e herpesvírus bovino tipo 5 (BHV-5). Bovinos foram vacinados com duas doses de
vacina, aplicadas com um intervalo de 90 dias. Foi medido o título de anticorpos nos dias 0, 30, 90, 120, 180, 270 e 450 após a primeira
vacinação (DPV). Os títulos de anticorpos contra BHV-1.1 e BHV-1.2 foram significativamente maiores que os contra BHV-5, ao longo
do experimento. Enquanto todos os animais soroconverteram para BHV-1.1 e BHV-1.2 após a primeira dose de vacina, apenas dois em
23 animais (8,7%) soroconverteram para o BHV-5. No entanto, após o reforço, todos os animais soroconverteram contra BHV-1.1, 1.2 e
BHV-5. Aos 450 DPV, 79% (15/19 animais) e 84% (10/19) ainda se encontravam soropositivos para BHV-1.1 e BHV-1.2, enquanto
apenas 50% dos animais (10/19) se demonstraram positivos contra o BHV-5. Foi concluído que, embora uma vacina com alta capacidade
de indução de anticorpos contra o BHV-1 possa induzir anticorpos capazes de neutralizar o BHV-5, os níveis de tais anticorpos são
significativamente mais baixos e de menor duração do que aqueles induzidos contra BHV-1.1 e BHV-1.2.
UNITERMOS: BHV-1; BHV-5; Herpesvírus bovino; Vacina experimental; Vacina inativada; Anticorpos neutralizantes.
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